Plus Therapeutics, Inc. (PSTV) Analysis

NasdaqCM:PSTV 1 Year Share Price vs Fair Value Explore Plus Therapeutics's Fair Values from the Community and select...

Alright, here is ANOTHER DD for $PSTV, since we have seen AMAZING movement since last Wednesday. I spent a HUGE chunk of my morning getting all of this info and cleaned up the clutter so please listen up. And I hope you enjoy my DD! Every now and then, a tiny biotech stock sneaks under the radar before blowing the hell up. Think of it like getting in on a tech startup before they drop the app that changes the game. That’s where PSTV is sitting right now. And here’s the kicker...this one isn’t ...

Plus Therapeutics ($PSTV) presented updated Phase 1/2 data from the ReSPECT-LM trial of REYOBIQ™ (rhenium-186 obisbemeda) in leptomeningeal metastases (LM) — a devastating complication of brain and spinal cancers with virtually no good treatment options. Key takeaways: • Safety confirmed – intrathecal delivery was well-tolerated, no dose-limiting toxicities. • Clear efficacy signal – CSF tumor DNA levels fell, MRI responses observed, and several patients showed meaningful clinical benefit. •...

I came across this company recently, on news that they launched a new product: diagnostic on brain cancer: 1. CNSide : it runs a diagnostic on the patient to detect Brain cancer WITHOUT surgery, they have implemented it in Texas so far. 2. they have a drug (REYOBIQ) that targets incurable brain cancer 3. August 14-16 PSTV is going to present at the SNO/ASCO CNS Metastases Conference, where the whole world will see what they’re doing, how they are doing it and what they have achieved (this conf...

Holy crap. Every time I peel back another layer on PSTV, the story gets better — and I’m honestly wondering how this is still under the radar. ⸻ 1️⃣ This isn’t unproven tech — it’s already battle-tested • CNside, the liquid biopsy that detects tumor DNA in cerebrospinal fluid, has been in nationwide clinical use since 2020. • Doctors already know it. Hospitals already ran it. • PSTV acquired the full rights in 2024 from Biocept, who went bankrupt because of finances — not because the tech f...